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Steven Z. Pavletic,1 Shaji Kumar,2 Mohamad Mohty,3 Marcos de Lima,4
James M. Foran,5 Marcelo Pasquini,6 Mei-Jie Zhang,6 Sergio Giralt,4
Michael R. Bishop,1 Daniel Weisdorf 7Allogeneic hematopoietic stem cell transplantation (alloHSCT) is increasingly being used for treatment of hema-
tologic malignancies, and the immunologic graft-versus-tumor effect (GVT) provides its therapeutic effective-
ness. Disease relapse remains a cause of treatment failure in a significant proportion of patients undergoing
alloHSCTwithout improvements over the last 2-3 decades.We summarize here current data and outline future
research regarding the epidemiology, risk factors, and outcomes of relapse after alloHSCT. Although some fac-
tors (eg, disease status at alloHSCTor graft-versus-host disease [GVHD] effects) are common, other disease-
specific factors may be unique. The impact of reduced-intensity regimens on relapse and survival still need to
be assessed using contemporary supportive care and comparable patient populations. The outcome of patients
relapsing after an alloHSCT generally remains poor even though interventions including donor leukocyte infu-
sions can benefit some patients. Trials examining targeted therapies along with improved safety of alloHSCT
may result in improved outcomes, yet selection bias necessitates prospective assessment to gauge the real con-
tribution of any new therapies. Ongoing chronic GVHD (cGVHD) or other residual post-alloHSCTmorbidities
may limit the applicability of new therapies. Developing strategies to promptly identify patients as alloHSCT
candidates, while malignancy is in a more treatable stage, could decrease relapses rates after alloHSCT. Better
understanding and monitoring of minimal residual disease posttransplant could lead to novel preemptive treat-
ments of relapse. Analyses of larger cohorts throughmulticenter collaborations or registries remain essential to
probe questions not amenable to single centeror prospective studies. Studies need to providedatawith detail on
disease status, prior treatments, biologic markers, and posttransplant events. Stringent statistical methods to
study relapse remain an important area of research. The opportunities for improvement in prevention andman-
agement of post-alloHSCTrelapse are apparent, but clinical discipline in their careful study remains important.
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blood (UCB) are being used.There is an increasing shift
toward nonmyeloablative (NMA) or reduced-intensity
conditioning (RIC) regimens designed to limit
treatment-related mortality (TRM) and expand
HSCT opportunities for older patients and those with
clinical comorbidities. Through all these advances,
malignant relapse remains the main barrier to more
successful alloHSCT. We summarize current data and
outline future research regarding the epidemiology,
risk factors, and outcomes of relapse after alloHSCT.GRAFT-VERSUS-HOST DISEASE (GVHD)
AND ITS IMPACTON RELAPSE
GVHD and Graft-versus-Leukemia (GVL)
The clinical syndrome of GVHD is strongly linked
to the allogeneic antineoplastic effect ofHSCT therapy,
the GVL or GVT effect [1]. Although separable in ex-
perimental murine studies, in humans, the distinction
between GVHD and GVT is less apparent. Numerous
reports have suggested reduced riskof relapse inpatients
with mild to moderate GVHD, but mortality from
severe GVHD precludes a survival benefit despite its
accompanying GVT [1]. In acute leukemias, chronic
myelogenous leukemia (CML), and indolent lympho-
proliferative diseases (e.g., chronic lymphocytic leuke-
mia and follicular lymphoma), a potent GVT effect is
recognized. Particularly in the leukemias, clinical
evidence suggests that the protective GVL effect
accompanies even mild or moderate GVHD [2]. Suffi-
cient alloreactivity to induce complete donor chimerism
may augment the GVL effect even in the absence of
clinical GVHD symptoms, although a threshold or
biomarker to identify sufficient donor-derived alloreac-
tivity to prevent recurrence is not defined. Strategies to
prevent GVHD, including ex vivo or in vivo T cell
depletion, therefore, must be tempered by concern
about lessening the antineoplastic effect of the allograft.Impact of chronic GVHD (cGVHD) on Relapse
Several observational studies demonstrate that
cGVHD is associated with lower relapse rates [1,3-11].
However, the biologic mechanisms of this important
GVT effect are poorly understood and are hampered
by imprecision of the GVHD diagnosis. In 2254
patients with either acute myelogenous leukemia
(AML) or acute lymphocytic leukemia (ALL) in first
complete remission (CR1) or CML in chronic phase,
cGVHD or acute GVHD (aGVHD) plus cGVHD led
to lower relative risks of relapse compared to patients
without GVHD (relative risk [RR]5 0.43, P5 .01 and
RR 5 0.33, P 5 .0001, respectively). Relapse rates with
identical twin donors or T cell-depleted grafts were
higher (RR5 2.09, P5 .005 and RR5 1.76, P5 .002,respectively) [1]. Similar findings were not confirmed in
lymphoma patients receiving AlloHSCT [12]. Recent
analyses by the Center for International Blood and
Marrow Transplant Research (CIBMTR) confirmed
that cGVHD (but not aGVHD) was associated with
lower relapse risk in all leukemias (AML: RR 5 0.75,
ALL:RR5 0.69, andCML:RR5 0.67) [2], but because
of increasedTRM, it did not improve leukemia-free sur-
vival (LFS). Leukemia relapseswere uncommonafter the
development of cGVHD (8%-9%; RR range: 0.5-0.6;
P\ .01), but increasing severity of cGVHD neither de-
layed nor lessened the risk of relapse. Patients with mild
cGVHD had the best LFS [4,8,9]. In 322 patients who
received RIC alloHSCT, grade II to IV aGVHD had
no impact on the risk of disease relapse/progression,
whereas extensive (but not limited) cGVHD reduced
risks of disease relapse/progression (hazard ratio
[HR] 5 0.4; P 5 0.006) [13]. The antitumor effects
of cGVHD may contribute to the success of RIC
transplants [14,15].
GVL and Alternative Donors
Enhanced alloreactivity accompanying greater
donor:recipientHLAdisparity has longbeen postulated
to yield a more potent GVL effect and lesser risks of
relapse [16]. Formal comparisons of URD andmatched
sibling transplants, recently published from the
CIBMTR, contradict this conventional wisdom [2,17].
Two reports, 1 examining leukemias and 1 in chronic
phase CML, observed a higher incidence of GVHD
with greater HLA disparity, but no augmented GVL
effect [2,17]. It, therefore, remains to be demonstrated
that relapse risks can be reduced by selecting
a disparate and thus more alloreactive donor, at least
through HLA allele level matching. Additional genetic
inputs associated with natural killer (NK) alloreactivity
(killer cell immunoglobulin-like receptor [KIR] ligand
matching, KIR ligand absence, or KIR genotyping)
may further modify this effect, but GVL is not aug-
mented by greater HLA disparity [18-20].
In 1072 UCB transplant patients, 28% developed
cGVHD, and multivariate analysis demonstrated
a reduced relapse rate and improved disease-free
(DFS) and overall survival (OS) (RR 0.65, 0.64, and
0.71 respectively) [21]. Generally, UCB grafts have
not led to higher relapse risks [22]. Recent data suggest
reduced relapse using double versus single cord grafts in
acute leukemias, and a prospective United States Blood
andMarrowTransplantClinicalTrialsNetwork (BMT
CTN) trial is testing this in pediatric leukemia [23].
Future Research
Along withGVL potency, the biologic characteris-
tics of a specific malignancy may also affect cGVHD-
related GVT [10]. cGVHD is not a single disease, but
an autoimmune syndrome driven by diverse immune
Biol Blood Marrow Transplant 16:871-890, 2010 873Epidemiology of Relapse after Allotransplantationprocesses; thus, dissection of the biologic components
of cGVHD associated with GVT needs analysis of
both the cGVHDand the antitumor response [24]. Ac-
tive cGVHD could limit the progression of relapsed
cancer, but its associated comorbidity may preclude
use of donor leukocyte (a.k.a. lymphocyte) infusion
(DLI) or other immune mediators. Understanding
this biology may identify new therapies.GVHD PROPHYLAXIS AND RELAPSE
Graft-versus-host disease prophylaxis in alloHSCT
with unmanipulated grafts often includes immunosup-
pressive agents that prevent or attenuate aGVHD.
Calcineurin inhibitors (e.g., cyclosporine [CsA] or
tacrolimus) plus methotrexate (MTX) successfully limit
aGVHD, although this combinationwas associatedwith
higher rates of disease relapse [25-28], particularly using
higher doses of calcineurin inhibitors [29].
Graftmanipulationwithex vivoTcell depletion suc-
cessfully reduces ratesof aGVHD,but increments indis-
ease relapse have been observed [30-32]. A prospective
trial comparing T cell depletion with pharmacologic
GVHD prophylaxis in URD alloHSCT demonstrated
faster engraftment, lower rates of aGVHD, but higher
cytomegalovirus infections and a significant increase in
CML relapse [33]. The particular sensitivity of CML
to GVL highlights the deleterious effect of potent T
cell depletion on relapse, although in some diseases,
GVL can be maintained [34].
Lymphocyte-specific antibodies such as antithy-
mocyte globulin (ATG) and alemtuzumab may reduce
the risk of GVHD, and are often used with URD
alloHSCT. This in vivo T cell depletion can improve
URD alloHSCT because of lower TRM and less
aGVHD [35-40]. Alemtuzumab-based prophylaxis
was associated with increased risk of relapse and death
from viral reactivation in patients with myelodysplastic
syndromes (MDS) and AML, with relapse responsible
for 60% of deaths [41]. Alemtuzumab or ATG in the
RIC regimen may increase relapse in multiple mye-
loma [42,43]. Other comparative studies including
different diseases did not demonstrate excessive
relapse rates using ATG or alemtuzumab [36,44,45].
Future Research
Tacrolimus (TAC) instead of CsA or mycopheno-
late mofetil (MMF) or sirolimus replacing MTX may
show promise as GVHD prophylaxis without many
side effects frequently seen with CsA/MTX combina-
tions [46-50]. Prospective testing of TAC plus MTX
combinations for related and URD alloHSCT led to
less grade II-IV aGVHD without differences in
cGVHD or disease relapse, but no improvements in
survival [48,51]. MMF plus CsA or TAC is widely
used with RIC, although only limited data citing theefficacy and impact on relapse are available. Small
studies with MMF or with added prednisone do not
report increased disease relapse [49,52]. Sirolimus/
TAC6MTX did not alter relapse [47]. Some preclin-
ical data suggests that sirolimus in the absence of CsA
or TAC is permissive for regulatory T cells (Tregs),
which can modulate the alloreactive response [53].
Limiting GVHD prophylaxis by decreasing the dose
and duration of CsA use led to increases in aGVHD
and cGVHD, but reduced relapse rates compared to
standard dose prophylaxis [54].COMMON FACTORS AFFECTING RISKOF
RELAPSE
Disease and Disease Status
The most common factors affecting the risk of
relapse include disease, disease status, chemotherapy
sensitivity, and the intrinsic disease sensitivity to
GVL [55] (Table 1). Additional factors include the
graft source, graft manipulation, and the conditioning
regimen utilized for the AlloHSCT [55-58]. In a meta-
analysis of trials where patients were randomized to re-
ceive either PBSC or BM allografts [56], PBSCs led to
faster neutrophil and platelet engraftment and more
grade III/IV aGVHD and extensive cGVHD, but
lower relapse rates (21% versus 27% at 3 years; odds
ratio [OR] 5 0.71; 95% confidence interval [CI],
0.54 to 0.93; P 5 .01). The relapse protection was ap-
parent in patients with advance (33% versus 51%) and
early disease (16% versus 20%). Retrospective registry
analyses indicate increased rates of extensive cGVHD
with PBSCs, without clear reduction in relapse,
although heterogeneity may obscure a potential bene-
fit [55,57]. Prospective testing of PBSCs versus BM in
URD grafting is underway through the BMT CTN.
Relative to the impact of the conditioning regimen
intensity on relapse, some comparison studies
suggest higher relapse rates after RIC than after MA.
However, this question needs prospective testing in
comparable cohorts of patients [58].Risk Factors for Relapse in AML
Compared with other therapies, alloHSCT results
in superior DFS and OS for patients with intermedi-
ate- and poor-risk AML [59]. Unfortunately, relapse
remains the major cause of treatment failure after
alloHSCT in AML, particularly for patients with
advanced disease.
Disease characteristics
The risk of AML relapse is best defined by disease
stage at time of alloHSCT and cytogenetic profile.
Patients in CR1 have less risk than those beyond
CR1. Moreover, although alloHSCT can rescue
Table 1. Epidemiology and Natural History of Relapse Following Allogeneic HCT
Risk factors for relapse Relapse incidence post allo-HCT Outcome post relapse
Risk factors
influencing outcome Areas needing study
Acute Myeloid Leukemia
- Transplant beyond first complete remission
- Poor risk cytogenetics
- FLT3-ITD mutations
- Secondary AML (prior chemo/radiotherapy)
- Age >60 years
- Comorbidities
- Precedent MDS
- HLA-matching
- Single CB transplantation
- Gender donor/recipient combinations other than F/M
- Specific KIR haplotypes
- Reduced intensity and non-myeloablative conditioning
- In vitro and in vivo T cell depletion
- AML in CR1: 10-40%
- Advanced disease stage: >40-50%
- After RIC allo-HCT: 18-50%
- Generally poor long-term
survival
- Limited DLI response
- Patient age
- Remission duration
- Use of DLI
- Favorable cytogenetics
- Presence of comorbidities
at relapse
- Disease stage upon relapse
(e.g. lower tumor burden
at relapse)
- Impact of novel therapies (hypomethylating
agents, HDAC inhibitors etc.)
- Impact of new molecular classifications
- Incidence of relapse after haploidentical
and cord blood transplants
- Preferred timing of transplantation in
light of rapid availability of haploidentical
and UCB vs. URD allo-HCT
- Role of maintenance therapies after allo-HCT
(prophylactic DLI, hypomethylating agents etc.)
- Role of minimal residual disease
(MRD) detection in predicting relapse.
Myelodysplastic Syndrome
- MDS stage (IPSS or WPSS)
- Bone marrow blasts and cytogenetics
- Low-risk disease: 5-20%
- High-risk disease: 10-40%
- Generally poor; long-term
survival in 0-40%
- Patient age
- Patient PS
- Presence of comorbidities at
relapse (GVHD, infections etc)
- Disease stage upon relapse
- Remission duration
- Donor availability
Retrospective studies:
- Estimate relapse rates for patients undergoing
HSCT after hypomethylating agent treatment
(transplant at best response or after failure)
- Impact of new MDS classifications and
outcomes in transplantation
- Incidence of relapse after haploidentical
and cord blood transplants;
- Preferred timing of transplantation in light of rapid
availability of haploidentical and UCB vs. URD HSCT
Prospective studies:
- Hypomethylating agents, angiogenesis inhibitors
and other medications as maintenance therapy
after HSCT for high-risk of relapse patients.
- Role of MRD detection in predicting relapse and
defining need for further interventions post HSCT
Chronic Myelogenous Leukemia
- Age
- Disease stage
- Time interval from diagnosis to transplant
- Donor type
- Unclear if relapse rate is higher
with older age
- 20% (CP) to 65% (BP)
- >1-2 years worse results
Disease stage is the major
determinant of long-term
survival:
CP: 30-60%
AP: 10-40%
BC: 0-10%
- Patient PS
- Presence of comorbidities at
relapse (GVHD, infections etc)
- Disease stage upon relapse
- Remission -duration
- Donor availability
- Sensitivity to TKIs
- Influence of BCR-ABL kinase mutations
on HSCToutcomes
- Impact of new TKI in predicting peri-HCToutcomes
- Will patients who failed TKI pre-HCT
respond following a post-HCT relapse?
- Relapse rates/overall results after
transplants after alternative donor,
haploidentical and cord blood transplants
Acute Lymphoblastic Leukemia
- WBC
- Ph+; t(4;11)
- Time to CR1
- Duration of CR1
25-50% CR1
40-60% CR2
Short survival;
Limited DLI response
Early relapse worse; no other data - MRD assay pre HCT to predict;intervene
to prevent relapse
- Detailed epid study to predict relapse;
Pre-HCT risk factors
Young; mid adult; Older adult
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Aggressive Non-Hodgkin Lymphoma
- Chemoresistant & < complete remission
at transplant
- >3 lines prior chemotherapy
- T-cell phenotype better (PTCL, AITL, ALCL)
- Mantle-cell lymphoma better
- Increasing Age
- Prior Auto-SCT
- NMA conditioning
- Early Progression after 10 therapy (<12 months)
- Use of non-TBI conditioning
- Bone marrow involvement at transplant
- Elevated LDH at Transplant
9-30% sensitive
18-75% resistant
# 20% relapse
# 20% (higher if TCD)
* Relative risk of progression 3.0
Short survival & poor
response to DLI for
chemo-resistant disease
Very high relapse rates for salvage
allo-HCT after failed auto-SCT
(40-50% at 3 yrs) without clear
evidence of a plateau
- The presence of a graft-versus-lymphoma
effect in aggressive lymphoma is
controversial and further prospective
efforts to identify GVL are needed
(except for mantle-cell and T-cell lymphoma)
- Standardization of patient population definitions
including IPI score and molecular pathology
- Study of allo-HCT in rituximab-refractory
disease where auto-SCT may not be effective
- Impact of targeted or disease-specific
conditioning regimens
- Maintenance strategies
Indolent Non-Hodgkin Lymphoma
- Chemoresistant disease
- Transformed histology
- NMA conditioning
- Use of non-TBI conditioning
- Bone marrow involvement at transplant
- Rituximab within 6 months
- KPS #80%
- ‘‘Tandem’’ AutoSCT/ AlloSCT (selected
for more aggressive disease120)
40%
- <15% - Significant only on
univariate analysis
- Hazard Ratio for
relapse 5.47 (95% CI 1.5-21)
- Disease course tends to be
similar to underlying histology
- Palliative responses to
conventional therapies
and response to DLI
have been reported
- Incomplete or falling donor
chimerism not associated
with increase relapse
risk in all series
- Timing of allo-HCT
- Standardized definitions of patient
population & risk scores at allo-HCT (e.g. FLIPI)
- Impact of targeted or disease-specific
conditioning regimens
- Role in rituximab-refractory disease
Hodgkin Lymphoma
- Extranodal disease
- KPS <90%
- <CR at transplantation
- Bulky disease
- After RIC:
Low-dose TBI conditioning
Refractory disease
>3 lines prior therapy
Donor \: recipient _
- Pediatric:
Poor performance status
Refractory disease
RIC (vs. myeloablative)*after 9 months
following allo-HCT
Relative risk of relapse (95% CI):
3.1 (1.3-7.2)
2.5 (0.9-7.1)
70%
70%
70%
3.2 (1.2-8.4)
2.1 (1.0-4.4)
4.4 (1.0-19.0)
- Palliative responses to
post-relapse chemotherapy
& radiotherapy
- Rare durable responses
to DLI reported
- Lower risk of relapse with
haploidentical sibling donor
(Hazard Ratio for relapse
0.25, 95% CI 0.2-0.8) or URD
(HR 0.43, 95% CI 0.2-0.9)
- Alemtuzumab conditioning did
not impact relapse risk
- Further evidence of GVL
- Use of alternative donors (UCB or
haploidentical) validated in multicenter studies
- Impact of targeted or disease-specific
conditioning regimens
Chronic lymphocytic leukemia
- Chemorefractory disease
- Response >CR/PR
- Bulky disease
- T cell depletion
- Late donor chimerism
- Absence of cGVHD
2-48%
TCD 68%
Little data,
DLI responses 15-50%
- Detailed prospective epidemiology study
of CLL disease and transplant specific factors
that impact relapse
- Evaluation of pre and post transplant
MRD in predicting relapse
- Evaluation of CLL biology and lineage
chimerism and relapse
(Continued)
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Table 1. (Continued)
Risk factors for relapse Relapse incidence post allo-HCT Outcome post relapse
Risk factors
influencing outcome Areas needing study
Multiple Myeloma
- Poor patient performance status
- Gender donor/recipient combinations other than F/M
- Allo-HCT > 1 year from diagnosis
- Durie stage 3 at diagnosis
- Chemoresistant disease
- Elevated B2 microglobulin
- Deletion chromosome 13, deletion 17p
- RIC regimens
- T-cell depleted grafts
- Campath or ATG use
- Lack of complete response
- 50% at 5 years - Poor, DLI has efficacy
- OS post relapse 2-4 years
- Better outcome with
newer drugs
Retrospective:
- Impact of novel agent therapy and
response status at time of HCT
- Myeloablative vs. RIC conditioning regimens
- Tandem auto-allo vs. single allo
- Outcome of patients following relapse:
efficacy of DLI and efficacy of novel agents
Prospective:
- Evaluation of MRD following allo-HCT
- Maintenance therapy with novel agents
- Role of immunomodulatory drugs with
or with out prophylactic DLI
GVL
- URD not < Sib
- UCB similar but little data
- Presence of GVHD: but I/II>05III/IV
- Disease specific/phenotype specific
analysis of relapse with GVH
- Compare disease relapse after HCTusing
novel GVHD prophylaxis regimens to
standard calcineurin inhibitor and
methotrexate regimens
- Assess the need of in vivo T-cell depletion
antibodies (ATG or alemtuzumab) in
addition to GVHD prophylaxis in high-resolution
HLA match unrelated donor HCT
- Correlation of cGVHD features and relapse
- Impact of tumor biology on relapse in cGVHD
- Prospective cohort study with sufficient
detail of information on the disease relapse,
transplant and cGVHD characteristics
GVHD Prophylaxis
- Ex vivo T-cell depletion
- In vivo T-cell depletion by antibodies – inconclusive
- Higher dose and duration of calcineurin inhibitor (CSA)
- MMF vs. MTX in addition to calcineurin
inhibitor – no effect
- MTX vs. no in addition to
tacrolimus/sirolimus – no effect
- tacrolimus vs. CSA – no effect
- Study GVHD prophylaxis regimens that
do not require chronic immunossupression,
such as ex vivo T-cell depletion or
post transplant cyclophosphamide as
platform for disease specific cellular
therapy to reduce relapse.
- Compare disease relapse after HCTusing
novel GVHD prophylaxis regimens
to standard calcineurin inhibitor
and methotrexate regimens.
- Assess the need of in vivo T-cell depletion
antibodies (ATG or alemtuzumab) in addition
to GVHD prophylaxis in high resolution
HLA match unrelated donor HCT.
CB indicates cord blood; HSCT, hematopoietic stem cell transplantation; RIC, reduced-intensity conditioning; MDS, myelodysplastic syndromes; KIR, killer cell immunoglobulin-like receptor; GVHD, graft-versus-host
disease; UCB, umbilical cord blood, URD, unrelated donor; DLI, donor leukocyte infusion.
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lapse rate remains high at approximately 51% (95%
CI, 38%-65%) [60]. Estimates of relapse incidence
and survival for alloHSCT for AML in CR1 can be de-
rived fromprospective studies that allow for a ‘‘biologic
assignment’’ of donor/no donor comparison, at least
for sibling donor grafting. Koreth et al. [59] analyzed
prospective biologic assignment in clinical trials of
alloHSCT versus consolidation with conventional
chemotherapy or autologous HSCT or both for
AML in CR1 (24 international trials with 6007
patients). For alloHSCT the hazard ratio (HR) of
relapse or death for AML in CR1 was 0.80 (95% CI,
0.74-0.86). Although the value of alloHSCT in cyto-
genetic subsets of AMLhas been reported, molecularly
defined subsets have not been well studied. FLT3-
ITDmutations increase risk, whereasNPM1mutation
without FLT3-ITD or a normal karyotype confer
better prognosis [61-63]. Outcome of alloHSCT in
FLT3/ITD-positive AML showed a strong reduction
of relapse after alloHSCT with hazard ratios nearing
0.5 [63-65].
Patient characteristics
The median age at diagnosis of AML is approxi-
mately 65 years. Advanced age and preceding MDS are
predictors of increased post-HSCT relapse [66-68].
Outcome may be worse in older (.60 years) patients,
reflecting both underlying disease biology and
accompanying comorbidities. The increased relapse
risk with advancing age also reflects the higher
proportion of patients with adverse cytogenetics and/
or overexpression of MDR-1 [69]. However, a recent
CIBMTR analysis showed no increased relapse risk be-
cause of age alone [70]. Other patient-related factors,
such as number of prior chemotherapy regimens [68]
and patient race, may add further risk [71-73]. Baker
et al. [72] found that after alloHSCT, Hispanics had
higher risks of treatment failure (death or relapse;
RR 5 1.30; 95% CI, 1.08-1.54) and overall mortality
(RR5 1.23; 95% CI, 1.03-1.47).
Donor characteristics
Despite improvements in supportive care and
HLA matching, outcome following URD alloHSCT
for AML is still inferior to that after matched sibling
HCT [74,75]. UCB has been studied as an
alternative and the antileukemic effect of single UCB
transplant appeared comparable to URD adult
donor alloHSCT [22,76]. In addition, double UCB
transplantation may lead to a reduced relapse risk in
acute leukemia versus single-unit UCBT [77,78].
After controlling for GVHD as a time-dependent
covariate, a female donor into a male recipient of
alloHSCT reduces relapse compared to other donor/
recipient sex combinations [79]. Non-HLA-genetic
factors may also limit relapse after alloHSCT. Ina study of 448 transplants in AML patients, Cooley
et al. [18] showed that URD donors with KIR B
haplotypes confer significant survival benefit to pa-
tients undergoing T cell-replete alloHSCT, because
of a decreased relapse rate and the lower TRM.
Conditioning regimens
Most reports of RIC alloHSCT for AML are small
and heterogeneous for disease status and demograph-
ics. In the largest studies of RIC alloHSCT for
AML, the relapse rate ranged from 18% to 50%
[80]. Lower relapse rates are achieved during CR1
compared with more advanced disease [81]. Sequential
pre-HSCT consolidation chemotherapy might limit
leukemia relapse rates [82,83]. The European Group
for Blood and Marrow Transplantation (EBMT)
analyses suggest higher relapse rates with RIC
regimens, but similar DFS between myeloablative
(MA) and RIC regimens [84]. Shimoni et al. [85] stud-
ied this balance between dose intensity, disease relapse,
and TRM in 112 consecutive patients with AML/
MDS. TRM was higher after the MA Bu-Cy regimen,
but relapse rates were lower.
The inclusion of in vivo T cell depletion with ei-
ther ATG or alemtuzumab in an RIC regimen may
also increase the incidence of relapse [41,83].
Prospective trials are planned, but no clear guidelines
exist to choose the proper conditioning intensity for
patients in remission. RIC regimens are thought to
be inadequate for patients with active leukemia.
Risk Factors for Relapse in MDS
Disease characteristics
After alloHSCT,MDS reported relapse rates range
from20% to60%,depending upon the intensity of con-
ditioning and disease status [70,86-89]. (Table 1) MDS
stage remains the strongest predictor of relapse. Lower
risk disease, defined by the International Prognostic
Scoring System (IPSS) yields recurrence rates of 5%
to 20%, with long-term disease control in 30% to
70%. An ‘‘inverse’’ selection bias may send fewer early
MDS patients to alloHSCT because of available hypo-
methylating agents or lenalidomide [90-92]. Recent
transplant series include more patients with older
and advanced MDS. Poor prognosis cytogenetic
abnormalities, especially those involving chromosome
7, and BM blast percentage are the strongest
predictors of post-HSCT disease control [87-89].
Data on alloHSCT for therapy-related (a.k.a. sec-
ondary)MDS are uncertain, yet relapse is a major cause
of failure. The EBMT reported data of 461 alloHSCT
patients with therapy-related MDS or AML (median
age 5 40 years) [70]. The cumulative incidence of
TRM and relapse at 3 years was 37% and 31%, respec-
tively. Relapse was more common with active MDS,
abnormal cytogenetics, older age, and therapy-related
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651 years) undergoing RIC alloHSCT [87], TRMwas
similar in older cohorts, and at 3 years there was no age-
related difference in relapse (29% versus 33%), LFS
(36% versus 23%), and OS (39% versus 29%). Ad-
vanced disease was a significant risk factor for OS,
LFS, TRM, and relapse. Therapy-related MDS can
be controlled with alloHSCT, and a recent CIBMTR
report described only 31% incidence of relapse at 3
years for 857 patients with therapy-related AML and
MDS [93]. MDS is of intermediate sensitivity to
GVL effect, but the impact of regimen intensity on
transplant outcome is uncertain [94-97].
Donor characteristics
Younger donors or better HLAmatched URD can
result in modestly reduced TRM, but no augmented
GVL was associated with less well-matched URD
[79,98]. Patients without matched related or URD
may receive haploidentical or UCB HSCT. The
experience with haploidentical donor HSCT in MDS
is limited; no data clarifies the GVL potency and
relapse risk with these usually T cell-depleted HSCT.
In the context of AML transplanted in CR, relapse
using UCB is similar to or less than URD or related
donor HSCT [99,100].
Transplant characteristics
cGVHD can lower relapse incidence and im-
proved DFS and OS. In 1 study of 148 patients, lower
risk of relapse in de novo MDS patients followed ex-
tensive cGVHD and low or intermediate-1 risk IPSS
[101], but other studies differed [70,87]. For patients
with MDS and AML, GVHD may not limit relapse
because of the competing risk of GVHD-induced
mortality [86].
Mixed chimerism, particularly after RIC trans-
plantation, does not necessarily imply a poor progno-
sis, but its persistence may augment relapse risks [102].
Persisting evidence of recipient hematopoiesis may be
early manifestations of relapse, especially after MA
HSCT when mixed chimerism is unexpected.
Outcome after relapse
Rapidly evolving, refractory relapses of MDS after
alloHSCT are often associated with short survival,
whereas later or indolent recurrences are more likely to
receive therapy and to be considered for a second
HSCT [103]. Older age, comorbidities (including infec-
tions) andongoingGVHDare important considerations
dictating patients’ tolerance of further therapy. Long-
term survival is reported from 0% to 40% [86,103].
Future research
There is a need for retrospectives analyses on al-
loHSCT for MDS addressing several topics including:(1) timing of alloHSCT at best response to hypome-
thylating agent or after failure, as clear estimates of
relapse rates are unknown; (2) determination of the im-
pact of new MDS classifications in predicting HSCT
outcomes; and (3) determination of the incidence of
relapse after haploidentical and cord blood transplants,
particularly with their rapid availability [104].
Prospective studies are needed in the following areas:
(1) hypomethylating agents and other medications as
maintenance therapy after alloHSCT; (2) role of min-
imal residual disease (MRD) detection in predicting
relapse and defining need for further post-alloHSCT
interventions.Risk Factors for Relapse in CML
Most alloHSCT for CML are now performed only
for tyrosine kinase inhibitor (TKI) resistance or intol-
erance except in countries where TKI availability is
markedly limited by cost. The initial signs of CML re-
lapse following alloHSCT are determined by a rise in
BCR-ABL transcript level. BCR-ABL transcript levels
may fluctuate during the first 6 to 12 months after
alloHSCT and may not indicate inevitable leukemia
progression unless transcripts steadily rise over time.
Relapse from 20% to 65%, depend mostly on disease
stage at HSCT [17]. Late relapses do occur, and the
cumulative incidence at 15 years can be up to 17%,
even for patients in remission at 5 years [105,106].
Disease characteristics
CML stage at the time of alloHSCT is the stron-
gest predictor of relapse. Gratwohl et al. [107] and
the EBMT proposed a CML HCST scoring system
in the 1990s based upon risk factors of age, disease
stage, time from diagnosis to HSCT, donor type, and
donor-recipient sex (female donors being worse).
This can predict TRM and DFS (but not relapse with
survival at 5 years of 72%, 70%, 62%, 48%, 40%,
18%, and 22% for patients with scores 0, 1, 2, 3, 4, 5,
and 6, respectively. An update including HSCT from
1990 to 2004 (n5 13,416) showed half of low-risk pa-
tients alive at 20 years, and a low risk score (0 or 1 risk
factors) yielded 2-year survival of 80%. GVHD rates
remain high and risks of relapse are unchanged [108].
BCR-ABL kinasemutations-mediating TKI resistance
may not affect HSCT outcomes if adjusted for disease
stage, but recent data is limited [109].
Prior treatment with interferon or imatinib does
not worsen outcomes after alloHSCT [110,111].
Patients with chronic phase CML and a suboptimal
or transient response to imatinib may have a higher
mortality, but relapse rates are similar to historic
controls [111]. Treatment with other TKIs does not
increase TRM, but data are insufficient to evaluate re-
lapse rates [110].
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PBSC grafts may reduce TRM in advanced pa-
tients, but no consistent impact on relapse has been ob-
served in either sibling or URD grafts. As mentioned,
compared to related donors, URDHSCT do not yield
superior protection against relapse [17]. CML is very
sensitive to the GVL effect and RIC HSCT can yield
long-term disease control for chronic phase patients.
Fludarabine plus melphalan conditioning can be effec-
tive in advanced or older patients beyond chronic
phase, although TRM rates are high [111-114].
Outcome after relapse
Patients relapsing into chronic phase, cytogenetic,
or molecular relapses have the best prognosis using
either imatinib and/or DLI. Survival for patients
relapsing into accelerated phase is only 10% to 40%
and in blast phase is very poor.Withdrawal of immuno-
suppressionmay reinduce remission in a few of patients
relapsing with chronic phase or subclinical CML.
DLImay induce remission in up to 75% of patients
relapsing in chronic phase, but not in advanced disease.
GVHD (in 50%) or BM aplasia (\5%) are complica-
tions of DLI. Smaller cell infusions with lower T cell
doses or possibly CD8 depletion may limit GVHD. It
is unclear if patients who failed TKI pre-HSCT will
respond to TKI following a post-HSCT relapse, even
without documented BCR-ABL mutations [115-117].
Future research
Study of BCR-ABL mutations, and the impact of
new TKI in predicting peri-HSCT outcomes is still
needed. Relapse rates after transplants using alterna-
tive donor, haploidentical, and CB transplants remain
to be better defined.Risk Factors for Relapse in ALL
Disease characteristics
Factors predicting relapse for initial therapy of ALL
also predict risks of relapse following alloHSCT. High
WBC count at diagnosis, adverse cytogenetics such as
Ph1or t(4;11) aswell as amatureBphenotype and short
initial remission are all associated with higher incidence
of post-HSCT relapse [118-130]. In CR1, alloHSCT
yields 20% to 40% relapses [123-129]. Early reports
suggest limited relapse risks in adult CR1 patients
undergoing RIC HSCT [131-139]. Although no
studies have validated the utility of postallograft
consolidation or maintenance therapy, imatinib or
other TKIs have promise in reducing relapse risks in
Ph1 ALL [140-145].
For HSCT during CR2 or in later remission, re-
lapse risks are higher, ranging from 40% to 60% in
published series, but with lesser prognostic impact of
adverse high-risk features. For standard risk ALL,particularly in children where transplants in CR2 for
those with on-therapy initial relapse are indicated,
promising survival without recurrence is reported
[118,130,131,144,146,147]. Relapse incidences of
30% to 50% are reported though these risks are
higher in adults or those with high risk features
[118,121,130,132,141,145].
Transplant characteristics
Protection against relapse using alternative, URD
or UCB donors have been similar or worse than
HLA-matched HSCT [120,121,130-132,148-151].
No consistent better protection against relapse
follows partial matched or URD donors; the observed
GVL is not enhanced by the greater HLA disparity
[2]. HSCT during active relapse for ALL is most often
unsuccessful with.70% recurrence, although 10% to
20% of patients may survive (CIBMTR data, 2009).
Future research
Newer approaches including DLI, intensified con-
ditioning, peritransplant targeted therapy, or TKI
have not meaningfully increased survival of ALL
patients with relapse after alloHSCT. Identifying
high-risk patients for early allografting remains the
most promising approach to reduce relapse hazards.Risk Factors for Relapse in Multiple Myeloma
AlloHSCT provides durable disease control in
myeloma, but TRM and relapse remains the most im-
portant reasons for failure [152]. Most patients relapse
after alloHSCT at a median of 56 months [153]. Sim-
ilar studies of RIC HSCT showed 42.3% progression
at 3 years [154]. Two recent studies, which included
tandem autologous 1 RIC alloHSCT, had a median
time to relapse of 5 years [155,156].
Disease characteristics
The following characteristics have all been associ-
atedwith inferior outcome formyeloma patients under-
going AlloHSCT: transplant beyond 1 year from
diagnosis;.8 cycles of chemotherapy; beta-2microglo-
bulin (B2M).2.5 mg/dL; female patients transplanted
frommale donors; and Durie stage 3 disease. Advanced
and chemoresistant disease also leads to increased re-
lapse risk [157,158]. Among patients undergoing
tandem autologous 1 RIC alloHSCT, B2M .3.5 and
time to first autologous HSCT .10 months were
associated with increased relapse risk [156]. In a recent
series of RIC alloHSCT, the presence of del13(q14)
or del17(p13) led to increased risk of relapse [159]. In
a prospective EBMT study comparing tandem auto-
allo to tandem autologous HSCT, the auto-allo
HSCT led to lower relapse rates, among patients with
del13 [155].
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PBSC has been associated with a higher risk of
cGVHD without reduction in myeloma relapse
[160]. No specific conditioning regimens have en-
hanced prevention of relapse of myeloma, but with
conventional MA alloHSCT, progression at 5 years
was significantly lower for melphalan/total body
irradiation (TBI) (36.7%) compared with cyclophos-
phamide/TBI (80.8%) [163]. RIC regimens, often fol-
lowing an autograft may augment the risk of relapse,
but with less TRM [156,164]. Smaller studies suggest
that use of prophylactic DLI can limit the increased
relapse risk following T cell-depleted grafts. No
consistent data suggest less relapse accompanying
GVHD [43,155,156,158,161-164].
The depth of response from alloHSCT has an im-
pact on the risk of relapse. Molecular techniques for
measuring MRD suggest lower relapse rates in those
with PCR-negative disease. PCR assessment of
MRD after alloHSCT showed half achieving a molec-
ular CR versus 16% of autografts resulting in less re-
lapse and longer PFS (35 versus 110 months) [165].
Outcome following relapse after alloHSCT for
myeloma
Only limited data are available on outcome after re-
lapse following alloHSCT. In 63 patients refractory or
relapsed after RIC alloHSCT, DLI yielded a median
survival of 23.6months following relapse.Novel agents
(e.g., lenalidomide and bortezomib) may benefit some
patients relapsing after alloHSCT [156,166-169].
Following treatment with these novel agents or DLI,
the median OS was 3.7 years from relapse among the
51 patients who had relapsed after RIC alloHSCT.
Patients with cGHVD prior to relapse and HSCT
within 10 months of diagnosis had better outcomes
following relapse. For 23 patients treated with
bortezomib, the median PFS was 6 months with 21 of
23 patients alive at 6 months after relapse [167]. An-
other series using bortezomib reported 65% survival
at 18 months [168].
Future research
The treatment of myeloma has undergone a para-
digm shift in the recent years with the incorporation of
new drugs such as immunomodulatory drugs and
proteasome inhibitors. Studies need to be designed
to examine the question of using these drugs in the
context of maintenance post-SCT to decrease risk of
relapse as well as their use in conjunction with salvage
approaches such as DLI.
Risk Factors for Relapse in Lymphomas
AlloHSCT for lymphoma is often performed for
advanced disease or for progression after autologous
HSCT [170-174]. RIC regimens allow alloHSCT forolder or higher risk lymphoma patients, yet relapse
remains a common problem [174-176]. Survival after
relapse reflects the underlying disease histology, similar
to that reported after autologous HSCT [177,178];
however, survival is poor for aggressive histology or
pre-HSCT chemorefractory non-Hodgkin lymphoma
(NHL) [172,173]. Extended survival has been reported
following DLI alone or with additional conventional
therapy for chemosensitive histologies, especially
indolent lymphoma [179,180]. Histologic distinctions
and chemosensitivity are the most important
determinants of relapse risk and survival after relapse
[181-183]. A risk score based on observed relapses after
RIC conditioning has confirmed the observation that
the risk is low (approximately 20%) for indolent and
mantle cell lymphoma and for those in remission,
but high (50%-60%) for Hodgkin lymphoma (HL) and
aggressive NHL not in CR [184] The graft-versus-
lymphoma effect has not been well quantified after
alloHSCT [12].
Hodgkin lymphoma
Early experience with MA conditioning and al-
loHSCTdemonstratedprohibitiveTRM, limiting its ap-
plicationuntil development ofRIC [171].Unfortunately,
relapse remains common after alloHSCT for HL, in ex-
cessof 60%inmost series [174,181], and ismost common
in those with extranodal disease, Karnofsky performance
status\90%, and those not in CR.
Nearly half of HL patients undergoing alloHSCT
from matched related donors with a RIC regimen
experienced relapse; alemtuzumab did not affect the
relapse rate [185]. Survival was worse for refractory
disease, although 8 of 14 patients responded to DLI;
4 with a durable CR. The EBMT compared MA to
RIC regimens in 168 with HL; relapse occurred in
57% and was more common after RIC [15]. Bulky
and refractory disease at alloHSCT was associated
with increased relapse risk. Importantly, cGVHD
was associated with a lower relapse rate, suggesting
a GVL effect.
In 285 RIC alloHSCT, relapse occurred in 147
patients and was significantly more common with
refractory disease, .3 prior therapies and female do-
nor:male recipients [186]. Sixty-four with persistent
or progressive HL received DLI, and 13 of 41 evalu-
able patients achieved a CR [186]. Fifty-eight patients
undergoing RIC alloHSCT had a median PFS \5
months, although OS was .2 years, indicating that
some responded to further therapy (including 6 of 14
patients with DLI) [182]. A UK report described 38
RIC patients with 15 of 21 relapsing patients received
DLI and half responded [187]. A pediatric series was
similar except that durable response to DLI was infre-
quent [188]. Importantly, the relapse rate after NMA
conditioning was lower with haploidentical donor
[189]. The CIBMTR reported alloHSCT from
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relapse, 1-year PFS of 30% and OS of 56% [190].
Indolent lymphomas
MA alloHSCT from an MRD can cure some
patients with follicular and low-grade lymphoma. The
relapse risk is lower (15%-20%) [191-194] than other
lymphoma histologies [172,174,181,184,195], even
with RIC conditioning [175,196-198]. Transformed
indolent lymphoma, as expected, has a higher risk of
relapse [176] Rituximab given within 6 months of al-
loHSCT may lower relapse risk [199]. Relapse may re-
establish indolent disease with reported responsiveness
to DLI or to withdrawal of immunosuppression
[181,200] or rituximab [201]. Relapse in follicular lym-
phoma is associated with chemoresistant disease, RIC
conditioning, non-TBI MA conditioning, BM involve-
ment, KPS #80%, and tandem auto/ alloHCT (the
latter appears to reflect selection of patients for
tandem transplantation with clinically aggressive
disease) [197].
Aggressive lymphomas
AlloHSCT for aggressive lymphoma (e.g., diffuse
large B-cell lymphoma) is often used for progression
following auto-HSCT or chemorefractory disease
[173,174,195,197,202-205]. Relapse is particularly
common (up to 75%) for those not in CR, with
chemorefractory disease and after salvage alloHSCT
[176]. Survival following relapse of aggressive
lymphoma after alloHSCT is poor with infrequent re-
sponses to DLI [175,195,197,203,204,206]. Relapse
is more common after more than 3 lines of prior
chemotherapy, increasing age, early disease progression
after initial therapy, non-TBI conditioning, and mar-
row involvement or elevated LDH at transplant. In
contrast, relapse following alloHSCT for peripheral
T cell lymphoma andmantle cell lymphoma are signif-
icantly lower (20% or less), and DLI may be of value
[172,205,207-214].
Future research
A uniform definition of lymphoma risk is needed in
transplant studies, including resistant disease, patient
(IPI and FLIPI), and disease risk scores (germinal
center B cell phenotype); standard reporting of relapse
incidence and treatment are also needed. Outcomes
after alloHSCT plus clear indications for DLI would
be valuable. These data could define the best
lymphoma populations for alloHSCT.
Risk Factors for Relapse in Chronic lymphocytic
leukemia (CLL)
CLL is a more common indication for alloHSCT
[215]. Disease response after allogeneic transplantation
for CLL is delayed after either MA or RIC condition-ing and can take 3 ormoremonths to achievemaximum
response [216,217]. Relapse after MA HSCT for CLL
is reported at 5% to 32% [11,217-219]; relapse rates
after RIC alloHSCT are reported to be 5% to 48%,
which is approximately 10% higher than after MA
conditioning [217-221]. Nearly all recent reports of
alloHSCT for CLL use RIC. Late CLL relapses can
also occur in about 5% of patients [217,222].
Disease characteristics
Chemorefractory disease and disease status (CR or
PR versus advanced) are risk factors for relapse [223].
In 82 patients after NMA HSCT the only significant
factor for prediction of relapse was lymphadenopathy
$5 cm (71% versus 27%; P 5 .0004) [218].
AlloHSCT is effective both in good risk and poor
risk CLL. In 44 high-risk CLL patients with 17p dele-
tion (all heavily pretreated) who received RIC, the 4-
year cumulative incidence of progression was 34%.
More than 3 lines of chemotherapy andT cell depletion
with alemtuzumab led to higher risks of relapse [219].
Mixed T cell chimerism at day 90 and chemorefractory
disease, but not ZAP-70 positivity, were associated with
higher risk of disease progression [224].
Transplant characteristics
Complete donor chimerism and achievement of
MRD negativity by multicolor flow cytometry or
real-time quantitative PCR may predict extended
DFS [216,225,226]. cGVHD may limit CLL relapse
[11], but relapse rates are similar using either matched
related or URD [215,217,218,221].
Outcome after relapse
Data on outcome of CLL patients who relapse af-
ter alloHSCT are few. Some respond to DLI
[215,218]; some responses occur to withdrawal of
immunosuppression, rituximab, or DLI. Better
responses associate with 100% chimerism of donor
T cells [224].
Future research
Analyses of larger data sets through multicenter
collaboration or registries are needed to clarify the
limited data of alloHSCT for CLL. Details of disease
status, prior treatments, biologic markers, transplant
regimen, and posttransplant events are particularly
important.STATISTICAL METHODS FOR ANALYZING
RELAPSE AFTER HSCT
In cancer studies, researchers often need to analyze
competing risks data, where each subject is at risk of
failure from multiple (K) different causes. For
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type of failure for each subject. In HSCT studies, dis-
ease relapse and TRM are 2 common competing
events. In the medical literature, commonly 1 2 Ka-
plan-Meier estimate is used to compute the relapse
rate treating the competing event of TRM as censored
at the time of occurrence. This overestimates the inci-
dence of relapse in the presence of the competing risk
of TRM [227,228]. The cumulative incidence function
(CIF) is the probability of a specific event occurring at
or before a given time point t. It has been shown that
CIF is a proper summary curve for analyzing
competing risks data. For competing risks data, one
often wishes to study the covariate effects on the CIF
of a particular failure event.
Estimating and modeling the cause-specific hazard
function has been considered a standard approach for
competing risks data. The Cox proportional hazards
model is the most commonly used regression model
for all causes. Because the CIF reflects all competing
cause-specific hazard functions, this approach gives
a complex nonlinear modeling relationship for the cu-
mulative incidence curves. It is hard to summarize the
covariate effect and to identify the time-varying effect
on the CIF for a particular type of failure. New regres-
sion approaches have been developed tomodel the CIF
directly. Recently, Klein and Zhang [229],Martinussen
and Scheike [230], Pintilie [231], Klein and Moesch-
berger [232], andZhang et al. [233] reviewed somebasic
statistical methods for analyzing competing risks data.Univariate Analysis
It is important to report the cumulative incidence
rate for both competing events: relapse and TRM.
The sum of cumulative incidence of relapse and
TRM is the cumulative incidence rate of treatment
failure, which equals 1 minus the probability of
DFS. Often, we need to compare the relapse rates
between treatment groups. In practice, the log-rank
test has been commonly used and reported along
with the cumulative incidence curves by treatment
groups. The log-rank test compares the cause-
specific hazards of relapse, whereas the cumulative
incidence function of relapse is determined by
cause-specific hazards of both relapse and TRM.
Thus, in some studies the log-rank test may lead to
a different conclusion compared to the reported
cumulative incidences. Recently, Gray [234] devel-
oped a test, which directly compares the cumulative
incidence curves. This should be used to compare
the CIF of relapse between groups.
Currently, only a few statistical packages are avail-
able to implement CIF for competing risks data, and
even fewer packages can be used to compute Gray’s
test for comparing the cumulative incidence functions.
SAS macros have been developed to compute thecumulative incidence functions by various authors. Re-
cently, SAS v9.1 has included a macro (‘‘cumincid.sas’’)
to compute the CIF. Some add-on R packages can be
used to analyzing competing risks data. R is open
source software that is freely available at http://
www.r-project.org. The R-cmprsk [235] package can
be used to compute and plot the cumulative incidence
functions and perform Gray’s test to directly compare
the CIF. Scrucca et al. [236] provided a detailed guide
for analyzing competing risks data using the cmprsk
package though an HSCT example.
In HSCT studies, we may observe that the
treatment effect of relapse changes over time. The re-
searchers and patients often want to know when the
treatments have different relapse rates and which treat-
ments have higher relapse rates over time. We can plot
the difference of the 2 cumulative incidence relapse
curves along with the 95% simultaneous confidence
band. The time when the zero line lies outside of 95%
confidence band indicates when 2 cumulative incidence
functions aredifferent.A simulationmethod canbeused
to construct the 95% confidence band [237,238].Multivariate Analysis
InmanyHSCT studies, clinicians often need to as-
sess the effect of covariates on the relapse rate. This has
been done most commonly by fitting a Cox model,
whichmodels the cause-specific hazards of relapse. Re-
cently, new statistical methods have been developed to
directly model the CIF. The first approach models the
subdistribution hazard function, which can be used to
directly interpret the covariate effect on the CIF.
Fine and Gray [239] proposed a Cox type proportional
subdistribution hazards model that has been imple-
mented in R-cmprsk package. The second approach
models the CIF using a pseudovalue technique [240].
Klein et al. [241] developed a SAS macro and an R
add-on function to compute pseudovalues for censored
competing risks data. The third and final approach is
based on binomial regression models using the inverse
probability of censoringweighting techniques. Scheike
et al. [242] proposed a fully nonparametric regression
model and class general semiparametric regression
models. A R-timereg package has been developed for
the binomial regression modeling by Scheike et al.
[243] provided a detailed guide for using the R-timereg
package. Zhang et al. [233] described an overview of
modeling cumulative incidence function for competing
risks data.
To study the GVT effect, clinicians often need to
assess the GVHD effect on relapse. To analyze the
GVHD effect, we need to understand that GVHD
and death without GVHD are 2 competing risk events
and at the time of transplant, it is unknown whether
and when a patient will develop GVHD. We should
treat GVHD as a time-dependent covariate. The
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ates, can be used to model cause-specific hazards of re-
lapse. The SAS PHREG procedure implements this
time-dependent Cox modeling. In HSCT studies,
researchers may wish to model cumulative incidence
function directly with a time-dependent covariate.
It has been pointed out that including a time-
dependent covariate to directly model cumulative inci-
dence functions could lead to serious bias [244]. New
statistical methods to directly model the cumulative
incidence function with time-dependent covariates
are yet to be developed.CONCLUSION
Disease relapse remains a major cause of treat-
ment failure in a significant proportion of patients
undergoing alloHSCT without much improvement
over the last 3 decades. Although some factors (e.g.,
disease status at alloHSCT or GVHD effects) are
common, other disease-specific factors may be unique
to the risk of relapse after alloHSCT. The impact of
RIC regimens on relapse and survival still need to be
assessed using contemporary supportive care and
comparable patient populations. The outcome of pa-
tients relapsing after an alloHSCT generally remains
poor even though interventions including DLI can
benefit some patients. Trials examining targeted ther-
apies along with improved safety of alloHSCT may
result in improved outcomes, yet selection bias
necessitates prospective assessment to gauge the real
contribution of any new therapies. Ongoing cGVHD
or other residual post-alloHSCT morbidities may
limit the applicability of new therapies. Developing
strategies to promptly identify patients as alloHSCT
candidates, while malignancy is in more treatable
stage, could decrease relapses rates after alloHSCT.
Better understanding and monitoring of MRD post-
transplant could lead to novel preemptive treatments
of relapse. Analyses of larger cohorts through multi-
center collaborations or registries remain essential
to probe questions not amenable to single center or
prospective studies. Studies need to provide data
with detail on disease status, prior treatments, bio-
logic markers, and posttransplant events. Stringent
statistical methods to study relapse remain an
important area of research. The opportunities for
improvement in prevention and management of
post-alloHSCT relapse are apparent, but clinical dis-
cipline in their careful study remains important.ACKNOWLEDGMENTS
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